<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427035</url>
  </required_header>
  <id_info>
    <org_study_id>CSL112_1001</org_study_id>
    <secondary_id>2014-005520-10</secondary_id>
    <nct_id>NCT02427035</nct_id>
  </id_info>
  <brief_title>A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Pharmacokinetic, Safety and Tolerability Study of CSL112 in Adult Subjects With Moderate Renal Impairment and in Healthy Adult Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 multicenter, randomized, double-blind, placebo-controlled, ascending dose
      study to investigate the pharmacokinetics (PK), safety, and tolerability of CSL112 in adult
      subjects with moderate renal impairment and in healthy adult subjects with normal renal
      function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma apolipoprotein A-I (apoA-I) and phosphatidylcholine (PC) area under the curve (AUC)</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
    <description>Baseline corrected plasma apoA-I and PC AUC0-infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apoA-I and PC AUC0-last and AUC 0-t</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
    <description>AUC from time point zero to the last quantifiable time point before the analyte first returns to baseline (AUC0-last) and/or a partial AUC from baseline to time point t (AUC0-t) with and without baseline correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apoA-I and PC Cmax</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apoA-I and PC Tmax</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apoA-I and PC Volume of distribution during terminal phase</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apoA-I and PC clearance</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apoA-I and PC t1/2</measure>
    <time_frame>Before and at up to 10 time points (during up to 7 days) after infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretion of apoA-I (Ae0-t)</measure>
    <time_frame>Before and up to 48 hours after infusion</time_frame>
    <description>Amount excreted (Ae) of apoA-I over a collection interval 0-t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary excretion of apoA-I (%fe0-t)</measure>
    <time_frame>Before and up to 48 hours after infusion</time_frame>
    <description>Percent fraction excreted (%fe) of apoA-I in urine over time interval 0-t, calculated as Ae0-t/Dose x 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance of apoA-I</measure>
    <time_frame>Before and up to 48 hours after infusion</time_frame>
    <description>Renal clearance of apoA-I, calculated as Ae0-48/AUC0-48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sucrose(Ae0-t)</measure>
    <time_frame>Before and up to 48 hours after infusion</time_frame>
    <description>Amount of sucrose excreted over a collection interval 0-t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sucrose (%fe0-t)</measure>
    <time_frame>Before and up to 48 hours after infusion</time_frame>
    <description>Percent fraction excreted sucrose in urine over time interval 0-t, calculated as Ae0-t/Dose x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of sucrose (clearance)</measure>
    <time_frame>Before and up to 48 hours after infusion</time_frame>
    <description>Renal clearance of sucrose, calculated as Ae0-48/AUC0-48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction (ADR) or suspected ADR frequency (%)</measure>
    <time_frame>Up to approximately 127 days</time_frame>
    <description>The overall percentage of participants with adverse reactions or suspected adverse reactions:
That begin during or within 1 hour of an infusion; or
That may be causally related to the administration of the investigational product; or
For which the Investigator's causality assessment is missing or indeterminate; or
For which the incidence in an active treatment arm exceeds the exposure-adjusted incidence rate in the placebo arm by 30% or more, provided the difference in incidence rates is 1% or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in routine safety assessments</measure>
    <time_frame>Up to approximately 97 days</time_frame>
    <description>The number of participants with clinically significant changes in any of the following assessments: clinical laboratory tests, physical examinations, body weight, electrocardiograms, vital signs, immunogenicity testing, serology, nucleic acid testing or proteinuria findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically important change in drug-induced liver injury</measure>
    <time_frame>From baseline (before infusion) up to Day 16.</time_frame>
    <description>A clinically important change in drug-induced liver injury is defined as a change (from baseline) in alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or a change in total bilirubin greater than 2 times ULN, that is confirmed upon repeat measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically important change in renal status</measure>
    <time_frame>From baseline (before infusion) up to Day 16.</time_frame>
    <description>A clinically important change in renal status is defined as a serum creatinine (Cr) increase to ≥ 1.5 x the baseline value that is confirmed upon repeat measurement, or the need for renal replacement therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose AUC</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
    <description>Baseline corrected plasma sucrose AUC0-infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose AUC0-last and AUC 0-t</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
    <description>AUC from time point zero to the last quantifiable time point before the analyte first returns to baseline (AUC0-last) and/or a partial AUC from baseline to time point y (AUC0-t) with and without baseline correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose Cmax</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose Tmax</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose Volume of distribution during terminal phase</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose Clearance</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sucrose t1/2</measure>
    <time_frame>Before and at up to 7 time points (during up to 2 days) after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction (ADR) or suspected ADR frequency</measure>
    <time_frame>Up to approximately 127 days</time_frame>
    <description>The overall number of participants with adverse reactions or suspected adverse reactions:
That begin during or within 1 hour of an infusion; or
That may be causally related to the administration of the investigational product; or
For which the Investigator's causality assessment is missing or indeterminate; or
For which the incidence in an active treatment arm exceeds the exposure-adjusted incidence rate in the placebo arm by 30% or more, provided the difference in incidence rates is 1% or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with AEs</measure>
    <time_frame>After the start of infusion up to approximately 127 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL112</intervention_name>
    <description>CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
    <arm_group_label>Low</arm_group_label>
    <arm_group_label>High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
    <arm_group_label>Low</arm_group_label>
    <arm_group_label>High</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 to 85 years (inclusive) of age, with body weight 50 kg or more.

          -  Subjects with renal impairment (RI) must have stable chronic moderate RI (estimated
             glomerular filtration rate [eGFR] ≥ 30 and &lt; 60 mL/min/1.73 m2)

          -  Healthy subjects must have normal renal function (eGFR ≥ 90 mL/min/1.73 m2)

        Exclusion Criteria:

          -  Evidence of a clinically significant medical condition, disorder or disease

          -  Evidence of hepatobiliary disease

          -  Any clinically relevant abnormal laboratory test result

          -  Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its
             components

          -  Other severe comorbid condition, concurrent medication, or other issue that renders
             the subject unsuitable for participation in the study, including: history of cancer,
             low platelet count, bleeding disorder or coagulopathy, significantly altered
             electrocardiogram waveform, unstable glycemia control in subjects with diabetes, acute
             renal failure, recent donation or loss of blood

          -  Evidence or history of alcohol or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise D'Andrea, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site - 17101</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 17102</name>
      <address>
        <city>Munich</city>
        <zip>D-81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24101</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24102</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

